脂质体作为药物载体增强亚硒酸钠消退动脉粥样硬化

目的　研究脂质体作为心血管药物载体包裹亚硒酸钠 (Na2 Se O3)治疗动脉粥样硬化 (AS)。方法　 32只雄性新西兰大耳白兔随机分成 AS对照组 ,硒 (Se)治疗组和含硒脂质体 (Se- L PS)治疗组 ;超声法制备出特定含硒脂质体 (Se- L PS)。通过测量不同时段血浆 Se含量的变化 ,了解脂质体的稳定性 ;通过测定不同组织谷胱甘肽过氧化物酶 (GSH- PX)活性 ,推测脂质体的靶向性 ;病理学方法检查各对比组主动脉粥样斑块的面积和厚度。结果　 Se- L PS治疗组 ,注入药液后 1d,其血浆 Se含量仍处动态 (与用药 4 d后的相比 ,P<0 .0 5 ) ;其血液和心脏 GSH- PX活性上升明显高于 Se治疗组 (P<0 .0 5 ) ,而其肾 GSH- PX活性上升低于 Se治疗组 (P<0 .0 5 )。结论　直径 0 .5～ 0 .7μm的刚性脂质体具有一定靶向性 ,改变了 Se的分布去向 ,适合作心血管药物的载体 ,包封 Se后 ,消退 AS斑块更明显

Liposome as a drug-carrier enhances the effect of Na2SeO3 in eliminating Atherosclerosis

Objective To investigate the effect of Liposome encapsulating Na 2SeO 3 as a cardiovascular medicine carrier on the regression of experimental atherosclerosis(AS) in rabbits. Methods The needed liposome with quantitative selenium was made by means of ultrasound. The content of Se in plasma was evaluated at different times to determine the stability of the liposome, and the activity of GSH-PX to speculate the targetility of the liposome. The size and the thickness of the AS plaque of aorta were examined by pathological method. Results One day after injection, the content of Se in plasma of Se-LPS group was still in dynamics, it was significant higher than that of four-days after injection (P<0.05).The activity of GSH-PX in blood and cardiac were significant higher than that of Se group (P<0.05),but in kidney it was lower than that of Se group (P<0.05).Conclusion The liposome with a diameter of 0.5-0.7um has targetility, it changes the distribution of Se in the organism and has the quality to act as a cardiovascular medicine carrier. It enhances the eliminating of AS plaque.